Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: The time has arrived

Expert Opinion on Investigational Drugs

Volumn 12, Issue 12, 2003, Pages 1939-1949

  O'Neil, Bert H ^a   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; Angiogenesis inhibitors; Bevacizumab; Capecitabine; Cetuximab; Colorectal neoplasms; Drug therapy; Edotecarin; Epidermal growth factor receptor inhibitors; Epothilone B; Irinotecan; Metastatic; Oxaliplatin; Pemetrexed; Tezacitabine; Tyrosine kinase inhibitors

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANGIOSTATIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIPODOPHYLLOTOXIN DERIVATIVE; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IRINOTECAN; IXABEPILONE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; TEZACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; DISEASE MODEL; DRUG POTENTIATION; DRUG TARGETING; FEVER; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; ILEUS; METASTASIS POTENTIAL; MOUSE; NEUROPATHY; NEUTROPENIA; NONHUMAN; REVIEW; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VOMITING;

EID: 0347519273     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.12.1939     Document Type: Review

References (70)

1. HOFF PM, ANSARI R, BATIST G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. (2001) 19:2282-2292.
2. VAN CUTSEM E, TWELVES C, CASSIDY J et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. (2001) 19:4097-4106.
3. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
4. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041-1047.
5. DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18:2938-2947.
6. GOLDBERG RM, MORTON RF, SARGENT DJ et al.: N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1009).
7. COMELLA P, MASSIDDA B, FILIPPELLI G et al.: Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0103) randomized study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1123).
8. TOURNIGAND C, LOUVET C, QUINAUX E et al.: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a Phase III study. Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 494).
9. ROTHENBERG ML, OZA AM, BIGELOW RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. (2003) 21:2059-2069.
10. ROTHENBERG ML, OZA AM, BURGER B et al.: Final results of a Phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorecral cancer following irinotecan, 5-FU, and leucovorin. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1011).
11. TAYLOR EC, KUHNT D, SHIH C et al.: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase J. Med. Chem. (1992) 35:4450-4454.
12. VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:2636-2644.
13. SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:1556-1561.
14. NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer. Ther. (2002) 1:545-552.
15. RINALDI DA, BURRIS HA, DORR FA et al.: Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. (1995) 13:2842-2850.
16. JOHN W, PICUS J, BLANKE CD et al.: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a Phase II study. Cancer (2000) 88:1807-1813.
17. RAYMOND E, LOUVET C, TOURNIGAND C et al.: Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int. J. Oncol. (2002) 21:361-367.
18. ATKINS JN, JACOBS S, WIEAND S et al.: Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a Phase II trial of the NSABP foundation research program. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1108).
19. KROENING H, HOCHSTER H, GROTHEY A et al.: Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer: A Phase I dose escalation study. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1459).
20. LINN SC, GIACCONE G: MDR1/P-glycoprotein expression in colorectal cancer. Eur. J. Cancer (1995) 31A.1291-1294.
21. BOLLAG DM, MCQUENEY PA, ZHU J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55:2325-2333.
22. LEE FY, BORZILLERI R, FAIRCHILD CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7:1429-1437.
23. ROTHERMEL J, WARTMANN M, CHEN T, HOHNEKER J: EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin. Oncol. (2003) 30:51-55.
24. ENG C, KINDLER HL, SKOOG L et al.: The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1134).
25. POPLIN E, MOORE M, O'DWYER P et al: Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 Phase II trials. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1135).
26. MEKHAIL T, CHUNG C, HOLDEN S et al.: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc. Am. Sec. Clin. Onc. (2003) 22 (Abstract 515).
27. YOSHINARI T, OHKUBO M, FUKASAWA K et al.: Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. (1999) 59:4271-4275.
28. PECK R: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Onc. (2000) 19 (Abstract 767).
29. LEWIS L, PEREZ R, PETROS W et al.: a Phase-I study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc. Am. Soc. Clin. Onc. (2000) 19 (Abstract 688).
30. YAMADA Y, YAMAMOTO N, SHIMOYAMA T et al.: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Onc. (2002) 21 (Abstract 385).
31. NAHUM K, SHIBA D, PADAVANIJA P et al.: Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1099).
32. RODRIGUEZ GI, JONES RE, ORENBERG EK, STOLTZ ML, BROOKS DJ: Phase I clinical trials of tezacitabine, [(E)-2′-deoxy-2′-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin. Cancer Res. (2002) 8:2828-2834.
33. BROOKS DJ, COX J, BERMAN BS et al.: Phase II study of tezacitabine in subjects with advanced/recurrent colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1122).
34. FERNANDO NH, HURWITZ HI: Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. (2003) 30:39-50.
35. WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95:1789-1797.
36. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
37. HILLAN KJ, KOEPPEN HKW TOBIN P et al.: The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc. Am. Sec. Clin. Onc. (2003) 22 (Abstract 766).
38. JOHNSON DH, DEVORE R, KABBINAVAR F et al.: Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 1256).
39. HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 3646).
40. MARX J: Angiogenesis. A boost for tumor starvation. Science (2003) 301:452-454.
41. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J Med. (2001) 344:783-792.
42. MENDELSON J: Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. (2000) 6:747-753.
43. SCHREIBER AB, WINKLER ME, DERYNCK R: Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science (1986) 232:1250-1253.
44. NEAL DE, MARSH C, BENNETT MK et al.: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 1:366-368.
45. GOLDSTEIN NS, ARMIN M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV Colon Adenocarcinoma: implications for a standardized scoring system. Cancer (2001) 92:1331-1346.
46. CHRISTEN RD, HOM DK, PORTER DC et al.: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest. (1990) 86:1632-1640.
47. FAN Z, BASELGA J, MASUI H, MENDELSOHN J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. (1993) 53:4637-4642.
48. LADEROUTE KR, AUSSERER WA, KNAPP AM, GRANT TD, SUTHERLAND RM: Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res. (1994) 54:1407-1411.
49. WOLLMAN R, YAHALOM J, MAXY R, PINTO J, FUKS Z: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30:91-98.
50. WAKSAL HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. (1999) 18:427-436.
51. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc. Am. Soc. Clin. Onc. (2001) 20 (Abstract 7).
52. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1012).
53. SALTZ L, KIES M, ABBRUZZESE JL, AZARNIA N, NEEDLE M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 817).
54. YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev Oncol. Hematol. (2001) 38:17-23.
55. TABERNERO J, ROJO F, JIMENE E et al.: A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 770).
56. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21:2237-2246.
57. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302.
58. OZA AM, TOWNSLEY LL, SIUP, MAJOR D: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 785).
59. SPECTOR N, RAEFSKY E, HURWITZ H et al.: Safety, clinical efficacy, and biologic assessments from EGF 10004: A randomized Phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 772).
60. BELANGER M, JONES CM, GERMOND C, BERGER MS: A Phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 978).
61. SLICHENMYER WJ, ELLIOTT WL, FRY DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. (2001) 28:80-85.
62. WATERHOUSE DM, RINEHART J, ADJEI AA et al.: A Phase II study of an oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, or pancreatic cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 816).
63. BHATNAGAR A, CARMICHAEL J, COSGRIFF T et al.: A randomized, double-blind, placebo controlled Phase III study of monoclonal antibody 3H1 plus 5-fluorouracil (5-FU)/leucovorin (LV) in stage IV colorectal carcinoma. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1041).
64. WANG CY, CUSACK JC Jr., LIU R, BALDWIN AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat.. Med. (1999) 5:412-417.
65. CUSACK JC Jr, LIU R, HOUSTON M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. (2001) 61:3535-3540.
66. DREVS J, MROSS K, MEDINGE M et al.: Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases. Proc. Am. Soc. Clin. Onc. (2003) 22 Abstract 1142).
67. STEWARD WP, THOMAS AL, MORGAN B et al.: Extended Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1098).
68. TRARBACH T, SCHLEUCHER N, RIEDEL U et al.: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2003) 22 (Abstract 1144).
69. ELLIS LM: A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg. (2003) 69:3-10.
70. BERGERS G, SONG S, MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. (2003) 111:1287-1295.